Key result
Amiodarone use was associated with hospitalization for acute pancreatitis compared to other antiarrhythmics, with adjusted HRs ranging from 1.21 to 1.43 across dichotomized exposure definitions.
Why the study?
Amiodarone has a long half-life of 60 days that is often ignored in observational studies, prompting evaluation of how different exposure definitions affect its association with acute pancreatitis risk.
Does amiodarone use increase the risk of hospitalization for acute pancreatitis compared to other antiarrhythmic drugs?
Cohort (n=36,772)
Yes
Does amiodarone use increase the risk of hospitalization for acute pancreatitis compared to other antiarrhythmic drugs?
The association between amiodarone use and acute pancreatitis risk is relatively insensitive to different exposure definitions, including those accounting for its long half-life.
Answers are grounded in this paper and cite their sources.
May support pancreatitis monitoring with amiodarone; leaves open causality and clinical impact.
PURPOSE: The antiarrhythmic drug amiodarone has a long half-life of 60 days, which is often ignored in observational studies. This study aimed to investigate the impact of different exposure definitions on the association between amiodarone use and the risk of acute pancreatitis. METHOD: Using data from the Dutch PHARMO Database Network, incident amiodarone users were compared to incident users of a different type of antiarrhythmic drug. Eighteen different definitions were applied to define amiodarone exposure, including dichotomized, continuous and categorized cumulative definitions with lagged effects to account for the half-life of amiodarone. For each exposure definition, a Cox proportional hazards model was used to estimate the hazard ratio (HR) of hospitalization for acute pancreatitis. RESULTS: This study included 15,378 starters of amiodarone and 21,394 starters of other antiarrhythmic drugs. Adjusted HRs for acute pancreatitis ranged between 1.21-1.43 for dichotomized definitions of exposure to amiodarone, between 1.13-1.22 for dose definitions (per DDD) and between 0.52-1.72 for cumulative dose definitions, depending on the category. Accounting for lagged effects had little impact on estimated HRs. CONCLUSIONS: This study demonstrates the relative insensitivity of the association between amiodarone and the risk of acute pancreatitis against a broad range of different exposure definitions. Accounting for possible lagged effects had little impact, possibly because treatment switching and discontinuation was uncommon in this population.
No takes yet. Share an insight, caveat, or question.
Hempenius et al. (2019) conducted a cohort in Antiarrhythmic drug users (n=36,772). Amiodarone vs. Other antiarrhythmic drugs was evaluated on Hospitalization for acute pancreatitis (HR 1.21-1.43). Amiodarone use was associated with hospitalization for acute pancreatitis compared to other antiarrhythmics, with adjusted HRs ranging from 1.21 to 1.43 across dichotomized exposure definitions.
Synapse has enriched 10 related papers. Consider them for comparative context: